NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Orinase Diagnostic (tolbutamide sodium) is an injectable first-generation sulfonylurea diagnostic agent used to assess pancreatic beta cell function. It is administered intravenously to stimulate insulin secretion and evaluate endocrine pancreatic reserve in patients with suspected diabetes or pancreatic disorders.
LOE Approaching
This legacy diagnostic product faces declining relevance; teams are typically small and focused on maintaining existing market share in specialized diagnostic centers.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Orinase Diagnostic offers limited growth trajectory but provides deep expertise in legacy product management, diagnostic workflows, and specialized market dynamics. Career progression typically requires transition to pipeline products or rotation into operational leadership roles.
Product Manager (Diagnostic)Regulatory Affairs Specialist
Worked on ORINASE DIAGNOSTIC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.